SCHEMBL22704695

SCHEMBL22704695

Nc1ncnc2c([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)snc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 2/20 0.65
▸ GAPDH P04406 3/20 0.47
▸ ADORA3 P0DMS8 3/20 0.47
▸ DOT1L Q8TEK3 2/20 0.47
▸ DPP4 P27487 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ SLC28A1 O00337 1/20 0.47
▸ MAP3K7 O43318 1/20 0.47
▸ SLC28A2 O43868 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ ADORA2A P29274 1/20 0.47
▸ ADORA2B P29275 1/20 0.47
▸ ADORA1 P30542 1/20 0.47
▸ STAT6 P42226 1/20 0.47
▸ PI4KA P42356 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ PI4K2B Q8TCG2 1/20 0.47
▸ SLC29A1 Q99808 1/20 0.47
▸ PI4K2A Q9BTU6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3957194 0.79 HIF1A (1.00) HIF1AGAPDHADORA3DOT1LDPP4
SCHEMBL12261313 0.79 HIF1A (0.57) HIF1AGAPDHADORA3DOT1LDPP4
Formycin SCHEMBL4196088 0.74 HIF1A (0.55) HIF1AGAPDHADORA3DOT1LDPP4
SCHEMBL3297374 0.74 HIF1A (0.65) HIF1AGAPDHADORA3DOT1LDPP4
Formycin SCHEMBL10149284 0.74 HIF1A (0.55) HIF1AGAPDHADORA3DOT1LDPP4
Formycin SCHEMBL980049 0.72 HIF1A (0.61) HIF1AGAPDHADORA3DOT1LDPP4
Formycin SCHEMBL14074914 0.72 HIF1A (0.61) HIF1AGAPDHADORA3DOT1LDPP4
SCHEMBL3301771 0.72 HIF1A (0.58) HIF1AGAPDHADORA3DOT1LDPP4
Formycin SCHEMBL15262901 0.72 HIF1A (0.61) HIF1AGAPDHADORA3DOT1LDPP4
SCHEMBL4144251 0.72 HIF1A (0.52) HIF1AGAPDHADORA3DOT1LDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787833-B2 Modified cyclic dinucleoside compounds as sting modulators ALIGOS THERAPEUTICS, INC. (US) 2023-10-17 — — US disclosed
US-11787833-B2 Modified cyclic dinucleoside compounds as sting modulators ALIGOS THERAPEUTICS, INC. (US) 2023-10-17 — — US disclosed
US-20200369711-A1 MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS ALIGOS THERAPEUTICS, INC. 2020-11-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369711-A1 MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS STING1, CGAS, IRF3 HIF1A 1203/4885GAPDH 2973/4885ADORA3 378/4885
US-11787833-B2 Modified cyclic dinucleoside compounds as sting modulators STING1, CGAS, IRF3 HIF1A 1203/4885GAPDH 2973/4885ADORA3 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback